Researchers are giving good new with a new find on a drug to combat Irritable Bowel Syndrome with Constipation

Irritable Bowel Syndrome (IBS) affects a recorded 15% of the Western Population. One third of these patients are identified with (IBS-C). It is characterized by excruciating abdominal pain, bloating and diarrhoea/ constipation. Scientists have identified a new drug, Linaclotide, to relive this pain, based on human clinical trials. The drug affects the guanylate cyclase-C on the inner lining of the intestines by binding it with the receptor domain. Linaclotide increases fluid secretion into intestines. It reduces abdominal pain. Prior studies prove that it creates a physiological pathway in the gastrointestinal tract. This restricts pain in the intestinal nerve endings. Linaclotide is marketed by Ironwood Pharmaceuticals Inc. It’s known as Linzess® in U.S. In Europe, it is known as Constella. In China and Japan markets, Ironwood is conducting clinical trials through partnerships. Through its existing partnerships in Australia and New Zealand it is looking at reaching out to newer un-partnered markets.